|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | INT-767 improves histopathological features in a dietinduced ob/ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis显示文摘AIM To characterize the efficacy of the dual FXR/TGR5 receptor agonist INT-767 upon histological endpoints in a rodent model of diet-induced and biopsy-confirmed non-alcoholic steatohepatitis(NASH).METHODS The effects of INT-767 on histological features of NASH were assessed in two studies using Lep^(ob/ob)(ob/ob) NASH mice fed the AMLN diet(high fat with transfat, cholesterol and fructose). In a proof-of-conceptstudy, Lep^(ob/ob)(ob/ob) NASH mice were first dosed with INT-767(3 or 10 mg/kg for 8 wk). A second ob/ob NASH study compared INT-767(3 and 10 mg/kg) to obeticholic acid(OCA)(10 or 30 mg/kg; 16 wk). Primary histological endpoints included qualitative and quantitative assessments of NASH. Other metabolic and plasma endpoints were also assessed. A comparative assessment of INT-767 and OCA effects on drug distribution and hepatic gene expression was performed in C57 Bl/6 mice on standard chow. C57 Bl/6 mice were orally dosed with INT-767 or OCA(1-30 mg/kg) for 2 wk, and expression levels of candidate genes were assessed by RNA sequencing and tissue drug levels were measured by liquid chromatography tandem-mass spectrometry.RESULTS INT-767 dose-dependently(3 and 10 mg/kg, PO, QD, 8 wk) improved qualitative morphometric scores on steatohepatitis severity, inflammatory infiltrates and fibrosis stage. Quantitative morphometric analyses revealed that INT-767 reduced parenchymal collagen area, collagen fiber density, inflammation(assessed by Galectin-3 immunohistochemistry) and hepatocyte lipid droplet area following INT-767 treatment. In a comparative study(16 wk), the FXR agonists OCA(10 and 30 mg/kg) and INT-767(3 and 10 mg/kg) both improved NASH histopathology, with INT-767 exerting greater therapeutic potency and efficacy than OCA. Mechanistic studies suggest that both drugs accumulate similarly within the liver and ileum, however, the effects of INT-767 may be driven by enhanced hepatic, but not ileal, FXR function. CONCLUSION These findings confirm the potential utility of FXR and dual FXR/TGR5 activation as disease intervention strategies in NASH. | Jonathan D Roth Michael Feigh Sanne S Veidal Louise KD Fensholdt Kristoffer T Rigbolt Henrik H Hansen Li C Chen Mathieu Petitjean Weslyn Friley Niels Vrang Jacob Jelsing Mark Young | 2018 | World Journal of Gastroenterology2018，24，2： | 7 |
| 2 | Targeting ryanodine receptors for anti-arrhythmic therapy显示文摘Antiarrhythmic 药是压制或阻止反常的心节奏的一组药品,它经常与实质的病态和死亡被联系。典型地指向血浆膜离子隧道的当前的 antiarrhythmic 药限制了临床的成功,在一些,情况被描述了为是支持 arrhythmic。然而,最近的研究建议钙的那个病理学的版本(从经由心脏的 ryanodine 受体(RyR2 ) 的 sarcoplasmic 蜂窝胃的 Ca 2+) 能为 antiarrhythmic 代表一个有希望的目标治疗。心脏舒张的 SR Ca 2+ 版本在两个被连接了到 arrhythmogenesis 继承心律不齐症候群“ catecholaminergic 多态的室的心悸亢进”并且心疾病的获得的形式(例如, atrial 纤维性颤动,心失败) 。药品的几个班被显示了减少反常 RyR2 活动并且可以通过 SR Ca 2+ 漏缝的减小对触发的心律不齐授与保护。在这评论,我们将为稳定 RyR2 评估当前的药理学方法并且基于分子的机制的当前的证据建议处理形式。 | Mark D McCAULEY | 2011 | Acta Pharmacologica Sinica2011，32，6： | 3 |
| 3 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 4 | 抑郁症的非药物治疗:系统性综述与证据图显示文摘背景抑郁症非药物治疗的疗效比较目前仍然不清楚。方法我们对一些系统性综述作了概述,回顾了随机对照试验(RCT),比较抑郁症非药物治疗的有效性和认知行为治疗(CBT)。对多个电子数据库在2016年2月之前发表的所有文献进行了检索,不限制语言。成对的评阅人进行资料纳入、数据提炼并评估偏倚的风险。在适用的时候进行了荟萃分析。结果我们收录了367项RCT,纳入了约2000名患者,进行了11种治疗,导出17项独立的头对头比较。通过标准化的量表评估,发现CBT、自然疗法、行为干预与躯体活动干预可以降低抑郁的严重程度。然而,这些非药物干预的相对疗效仍然缺乏。这些干预对临床缓解和复发的效果不清楚。CBT的发生率比抗抑郁药物更低。局限性由于证据缺乏一致性、证据不清或偏倚风险高,导致证据的质量只是低到中等,限制了我们研究结果的可信度。结论抑郁症的非药物治疗能减少抑郁症状,在轻度到重度抑郁症患者中,应当合并抗抑郁药物治疗,一同进行。对于非药物治疗的选择,应当根据患者的价值观、偏好、临床和社会因素来与患者共同作出决定。 | Wigdan H Farah Mouaz Alsawas Maria Mainou Fares Alahdab Magdoleen H Farah Ahmed T Ahmed Essa A Mohamed Jehad Almasri Michael R Gionfriddo Ana Castaneda-Guarderas Khaled Mohammed Zhen Wang Noor Asi Craig N Sawchuk Mark D Williams Larry J Prokop M Hassan Murad Annie LeBlanc | 2017 | 英国医学杂志中文版2017，20，11： | 2 |
| 5 | Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience显示文摘 | Phil A Hart Mark D Topazian Thomas E Witzig Jonathan E Clain Ferga C Gleeson Robin R Klebig Michael J Levy Randall K Pearson Bret T Petersen Thomas C Smyrk Aravind Sugumar Naoki Takahashi Santhi S Vege Suresh T Chari | 2013 | Gut2013，，11： | 2 |
| 6 | Percutaneous transluminal angioplasty balloons for endoscopic ultrasound-guided pancreatic duct interventions显示文摘BACKGROUND Endoscopic ultrasound(EUS)-guided main pancreatic duct(PD)access may be used when conventional endoscopic retrograde cholangiopancreatography(ERCP)techniques fail.The use of a percutaneous transluminal angioplasty balloon(PTAB),originally developed for vascular interventions,can be used to facilitate transmural(e.g.,transgastric)PD access and to dilate high-grade pancreatic strictures.AIM To describe the technique,efficacy,and safety of PTABs for EUS-guided PD interventions.METHODS Patients who underwent EUS with use of a PTAB from March 2011 to August 2021 were retrospectively identified from a tertiary care medical center supply database.PTABs included 3-4 French angioplasty catheters with 3-4 mm balloons designed to use over a 0.018-inch guidewire.The primary outcome was technical success.Secondary outcomes included incidence of adverse events(AEs)and need for early reintervention.RESULTS A total of 23 patients were identified(48%female,mean age 55.8 years).Chronic pancreatitis was the underlying etiology in 13(56.5%)patients,surgically altered anatomy(SAA)with stricture in 7(30.4%),and SAA with post-operative leak in 3(13.0%).Technical success was achieved in 20(87%)cases.Overall AE rate was 26%(n=6).All AEs were mild and included 1 pancreatic duct leak,2 cases of post-procedure pancreatitis,and 3 admissions for post-procedural pain.No patients required early re-intervention.CONCLUSION EUS-guided use of PTABs for PD access and/or stricture management is feasible with an acceptable safety profile and can be considered in patients when conventional ERCP cannulation fails. | Jad P AbiMansour Barham K Abu Dayyeh Michael J Levy Andrew C Storm John A Martin Bret T Petersen Ryan J Law Mark D Topazian Vinay Chandrasekhara | 2022 | World Journal of Gastrointestinal Endoscopy2022，14，8： | 2 |
| 7 | End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients显示文摘AIM To determine if end-stage renal disease (ESRD) is a risk factor for post endoscopic retrograde cholangio-pancreatography (ERCP) adverse events (AEs). METHODS We performed a retrospective cohort study using the Nationwide Inpatient Sample (NIS) 2011-2013. We identified adult patients who underwent ERCP using the International Classification of Diseases 9^(th) Revision (ICD-9-CM). Included patients were divided into three groups: ESRD, chronic kidney disease (CKD), and control. The primary outcome was post-ERCP AEs including pancreatitis, bleeding, and perforation determined based on specific ICD-9-CM codes. Secondary outcomes were length of hospital stay, in-hospital mortality, and admission cost. AEs and mortality were compared using multivariate logistic regression analysis.RESULTS There were 492175 discharges that underwent ERCP during the 3 years. The ESRD and CKD groups contained 7347 and 39403 hospitalizations respectively, whereas the control group had 445424 hospitalizations. Post-ERCP pancreatitis (PEP) was significantly higher in the ESRD group (8.3%) compared to the control group (4.6%) with adjusted odd ratio (aOR) = 1.7 (95% CI: 1.4-2.1, ~aP < 0.001). ESRD was associated with significantly higher ERCP-related bleeding (5.1%) compared to the control group 1.5% (aOR = 1.86, 95%CI: 1.4-2.4, ~aP < 0.001). ESRD had increased hospital mortality 7.1% vs 1.15% in the control OR = 6.6 (95%CI: 5.3-8.2, ~aP < 0.001), longer hospital stay with adjusted mean difference (aMD) = 5.9 d (95% CI: 5.0-6.7 d, ~aP < 0.001) and higher hospitalization charges aMD = $+82064 (95%CI: $68221-$95906, ~aP < 0.001). CONCLUSION ESRD is a risk factor for post-ERCP AEs and is associated with higher hospital mortality. Careful selection and close monitoring is warranted to improve outcomes. | Tarek Sawas Fateh Bazerbachi Samir Haffar Won K Cho Michael J Levy John A Martin Bret T Petersen Mark D Topazian Vinay Chandrasekhara Barham K Abu Dayyeh | 2018 | World Journal of Gastroenterology2018，24，41： | 2 |
| 8 | Large Molecular Hyperpolarizabilities. Quantitative Analysis of Aromaticity and Auxiliary Donor-Acceptor Effects显示文摘 | Albert I D L Marks T J Ratner M A | | 0，，： | 2 |
| 9 | Telangiectatic osteosarcoma:radiologic-pathologic comparison显示文摘 | Mark D M Suphanee wan Jaovisidha H Thomas T | 2003 | Radiology2003，229，： | 1 |
| 10 | Development of a laser Raman spectrometer for deep-ocean science显示文摘 | Peter G Brewer George Malby Jill D Pasteris Sheri N White Edward T Peltzer B Wopenka J Freeman Mark O Brown | 2004 | Deep-Sea Research Part I2004，，5： | 1 |
| 11 | Bacterial RNA chaperones confer abiotic stress tolerance in plants and improved grain yield in maize under water-limited condition 显示文摘 | Paolo C Dave W Robert J B Don C A Jay H Martin S Mark A Ganesh K Sara S Robert D Santiago N Stephanie B Mary F Jayaprakash T Santanu D Christopher B Michael H L Jacqueline E H | 2008 | Plant Physiology2008，147，2： | 1 |
| 12 | The hippocampus 显示文摘 | Mark L Daniels D Naidich T | 1993 | American Journal Of Neuroradiology1993，14，3： | 1 |
| 13 | The prensent status of QSAR in toxicology显示文摘 | T Wayne Schultz Mark T D Cronin | 2003 | Journal of Molecular Structure:THEOCHEM2003，622，12： | 1 |
| 14 | Estimating the environmental costs of soil erosion at multiple scales in Kenya using emergy synthesis 显示文摘 | Matthew J Cohen Mark T Brown Keith D Shepherd | 2006 | Agriculture Ecosystems and Environment2006，114，2： | 1 |
| 15 | A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome显示文摘 | Mark E Curran Igor Splawski Katherine W Timothy G.Michael Vincen Eric D Green Mark T Keating | 1995 | Cell1995，，： | 1 |
| 16 | Thin- Film Nonlinear Optical Diode 显示文摘 | Michael D T Mark J B Michael S | 1995 | Appl Phys Lett1995，66，： | 1 |
| 17 | 显示文摘 | ALBERT D L MARKS T J RATNER M A | 1997 | J Am Chem Soc1997，119，28： | 1 |
| 18 | Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation显示文摘 | Anscher M S Marks L B Shafman T D | | 0，，17： | 1 |
| 19 | Valuing public goods: a comparison of survey and hedonic approaches 显示文摘 | BROOKSHIRE D MARK T WILLIAM S | 1982 | The American economic review1982，72，1： | 1 |
| 20 | Single- pixel imaging via compressive sampling 显示文摘 | Marco F D Mark A D Dharmpal T | 2008 | IEEE Signal Process2008，25，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员